The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - A report of Polish Acute Leukemia Group (PALG) phase II study

Neoplasma

Volumn 49, Issue 6, 2002, Pages 405-411

  Wrzesien Kus, A ^a   Robak, T ^a   Jamroziak, K ^a   Wierzbowska, A ^a   Dmoszynska, A ^b   Adamczyk Cioch, M ^b   Kuliczkowski, K ^c   Mazur, G ^c   Holowiecki, J ^d   Konopka, L ^e   Maj, S ^e   Marianska, B ^e   Zawilska, K ^f  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Inst of Hematology Transfusiology   (Poland)

^f Department of Internal Diseases ^*  (Poland)

Author keywords

Acute myeloid leukemia; Elderly; Low dose therapy

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; ARABINOSIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLAST CELL; BLOOD TOXICITY; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; POLAND; QUALITY OF LIFE; SUPERINFECTION; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0036967849     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. ARCHIMBAUD E, JEHN U, THOMAS X, DE CATALDO F, FILLET G, BELHABRI A, PEAUD PY, MARTIN C, AMADORI S, WILLEMZE R. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13:843-849.
2. ARLIN Z, CASE DC, MOORE J, WIERNIK P, FELDMAN E, SALETAN S, DESAI P, SIA L, CARTWRIGHT K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1999; 4: 177-183.
3. BAUDARD M, MARIE JP, CARDIOU M, VIGUIE F, ZITTOUN R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.
4. CHESON BD, CASSILETH PA, HEAD DR, SCHIFFER CA, BENNETT JM, BLOOMFIELD CD, BRUNNING R, GALE RP, GREVER MR, KEATING MJ. Report of the National Cancer Insitute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Onco 1990; 8: 813-819.
5. DEGOS L, CASTAIGNE S, SILLY H, SIGAUX F, DANIEL MT. Treatment of leukemia with low dose ara-C: a study of 160 cases. Semin Oncol 1985; 12(Suppl 3): 196-199.
6. GRIMWADE D, WALKER H, HARRISON G, OLIVER F, CHATTERS S, HARRISON CJ, WHEATLEY K, BURNETT A, GOLDSTONE AH on behalf of the Medical Research Council Adult Leukaemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312-1320.
7. GRIMWADE D, WALKER H, OLIVER F, WHEATLEY K, HARRISON C, HARRISON G, REES J, HANN I, STEVENS N, BURNETT A, GOLDSTONE AH. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients enetred into the MRC AML 10 trial. The Medical Research Counsil Adult and Children's Leukaemia Working Parties, Blood 1998; 92: 2322-2333.
8. HARTMANN F, JACOBS G, GOTTO H, SCHWAMBORN J, PFREUNDSCHUH M. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leukemia & Lymph 2001; 42: 347-355.
9. HERNANDEZ-BOLUDA JC, SIERRA J, ESTEVE J, NOMDEDEU B, MONTSERRAT E. Treatment of elderly patients with AML: results of an individualized approach. Haematologica 1998; 83: 34-39.
10. LANCET JE, WILLMAN CL, BENNETI JM. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am 2000; 14: 251-267.
11. LIU YIN JA, JOHNSON PR, DAVIES JM, FLANGAN NG, GORST DW, LEWIS MJ. Mitozantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 1991; 79: 415-420.
12. LOPEZ A, DE LA RUBIA J, MARTIN G, MARTINEZ J, CERVERA J, JARQUE I, SEMPERE A, PLUME G, SAAVEDRA S, REGADERA A, SANZ G, GOMIS F, PEREZ-SIRVENT ML, SENENT L, JIMENEZ C, SANZ MA. Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leukemia Res 2001; 25: 685-692.
13. LOWENBERG B, SUCIU S, ARCHIMBAUD E. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low dose cytarabine for maintenance of remission and an assessement of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. J Clin Oncol 1998; 16: 872-881.
14. MANOHARAN A, BAKER RI, KYLE PW. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Am J Hematol 1997; 55: 115-117.
15. TAYLOR PRA, REID MM, STARK AL. De novo acute myeloid leukaemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Leukemia 1995; 9: 231-237.
16. TILLY H, CASTAIGNE S, BORDESSOULE D, CASASSUS P, PRISE PJ, TERTIAN G, DESABLENS B, HENRY AMAR M, DEGOS L. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272-279.
17. VISANI G, BERNASCONI P, BONI M, CASTOLDI GL, CIOLLI S, CLAVIO M, COX MC, CUNEO A, DEL POETA G, DINI D, FALZETTI D, FANIN R, GOBBI M, ISIDORI A, LEONI F, LISO V, MALGOLA M, MARTINELLI G, MECICCI C, PICCALUGA PP, PETTI MC, RONDELLI R, RUSSO D, SESSAREGO M, SPECCHIA G, TESTONI N, TORELLI G, MANDELLI F, TURA S. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-analysis of 848 patients. Leukemia 2001; 15: 903-909.
18. WAHLIN A, MARKEVARN B, GOLOVLEVA I, NILSSON M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukemia. British J Haematol 2001; 115: 25-33.